在IDH突变AML中的HMA/VEN治疗修改和相关结果
Kuo-Kai Chin1, Andriy Derkach2, Christopher Famulare1
1Leukemia Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Leukemia & lymphoma
|October 14, 2024
概括
低甲基化剂 (HMA) 和venetoclax (VEN) 组合显示在IDH突变 (IDHm) 急性髓性白血病 (AML) 中具有有效性. 治疗修改没有影响存活率,但长期毒性需要注意.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床研究 临床研究
背景情况:
- 低甲基化剂 (HMA) 和venetoclax (VEN) 是IDH突变 (IDHm) 急性髓性白血病 (AML) 的标准治疗方法,适用于无法接受诱导化疗的患者.
- 在IDHm AML中对HMA/VEN治疗修改的影响的现实数据有限.
研究的目的:
- 评估HMA/VEN治疗在IDHm AML患者的现实世界队列中的疗效和安全性.
- 评估治疗修改对反应率和整体存活率的影响.
主要方法:
- 从2018年1月到2023年6月,对89名IDHm AML患者进行了HMA/VEN治疗的回顾性审查.
- 分析反应率 (CR/CRi),整体存活率和治疗修改 (例如,VEN剂量减少,循环延长).
- 对不良事件的评估,包括中性质减退和住院治疗.
主要成果:
- 观察到高CR/CRi率:76%的新诊断 (ND) 和55%的复发/耐药 (R/R) 患者.
- 平均整体存活时间为29.2个月 (ND) 和17.1个月 (R/R).
- 早期VEN减少与反应降低有关,但与存活率无关;长期循环对结果没有影响. 发现了显著的中性质衰减和住院治疗.
结论:
- HMA/VEN是IDHm AML的有效治疗方法,其修改不会对存活率产生负面影响.
- 与HMA/VEN治疗相关的长期毒性需要谨慎管理.
- 现实数据支持HMA/VEN疗效,强调需要持续监测不良事件.
相关概念视频
Venous Thrombosis III: Interprofessional Care
3
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
3
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Heart Failure V: Medical Management
2
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
Acute Respiratory Failure-V
124
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
124
Myocarditis IV: Nursing Management
2
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
2


